| Symbol | Sector | Firm | Action | Grade | Target | Mkt Cap ▼ | Base | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TSLA | Consumer Cyclical | RBC Capital Mkts | Reiterates | Outperform | $480 | $1.2T | $309.22 | -1.1% | -0.6% | -3.0% | +3.5% | +0.8% | +3.5% |
| XOM | Energy | BofA Securities | Downgrade | Buy → Neutral | $158 | $641.6B | $154.77 | -0.4% | -1.1% | +2.4% | +0.1% | -1.0% | -0.2% |
| CRWD | Technology | Loop Capital | Initiates | Buy | $230 | $183.4B | $180.11 | +0.7% | +0.9% | -1.3% | +3.3% | +3.0% | +6.1% |
| SYK | Healthcare | UBS | Reiterates | Buy | $400 | $129.1B | $336.74 | +2.9% | +2.9% | +1.6% | -1.2% | -6.4% | +4.8% |
| ISRG | Healthcare | UBS | Initiates | Buy | $500 | $126.1B | $356.83 | +2.4% | +1.4% | -2.4% | -0.0% | +0.1% | +6.2% |
| MDT | Healthcare | UBSB | Upgrade | Neutral → Buy | $100 | $107.8B | $84.22 | +2.4% | +3.2% | +0.8% | -2.1% | -0.4% | +1.5% |
| INTU | Technology | TD Cowen | Downgrade | Buy → Hold | $304 | $83.1B | $303.91 | +0.6% | +3.0% | +6.4% | -5.3% | +0.2% | +0.7% |
| HON | Industrials | BofA SecuritiesA | Upgrade | Underperform → Neutral | $265 | $77.9B | $245.75 | +1.6% | +0.5% | -2.4% | +0.3% | +0.5% | +1.5% |
| BDX | Healthcare | UBS | Initiates | Buy | $19 | $57.6B | $158.92 | +1.9% | +4.7% | +1.2% | -1.8% | +0.1% | +2.8% |
| EW | Healthcare | UBS | Initiates | Buy | $110 | $47.8B | $83.04 | +1.9% | +0.8% | +2.5% | +1.4% | -1.0% | +3.2% |
| NTR | Basic Materials | BNP Paribas Exane | Upgrade | Neutral → Outperform | $80 | $32.4B | $67.40 | +1.3% | +3.1% | +1.6% | +0.2% | -2.3% | -4.5% |
| JBS | Consumer Defensive | JP MorganA | Upgrade | Neutral → Overweight | $18 | $30.1B | $13.55 | +3.1% | +2.8% | +2.2% | +0.4% | -1.9% | -1.9% |
| KOF | Consumer Defensive | HSBC Securities | Downgrade | Buy → Hold | $116 | $22.9B | $108.99 | -1.0% | -0.2% | -1.6% | +1.9% | -0.8% | -1.2% |
| IP | Consumer Cyclical | JP MorganA | Upgrade | Neutral → Overweight | $61 | $22.5B | $42.41 | +2.7% | +4.0% | -3.3% | +1.2% | -5.4% | +1.5% |
| STE | Healthcare | UBS | Initiates | Buy | $275 | $21.3B | $218.40 | +1.9% | +5.5% | +1.9% | -1.5% | -1.2% | +1.9% |
| CIB | Financial Services | Goldman | Upgrade | Neutral → Buy | $98 | $20.9B | $87.93 | +3.0% | +1.3% | +0.4% | +4.9% | -1.5% | -1.5% |
| ZBH | Healthcare | UBS | Initiates | Buy | $115 | $17.8B | $92.07 | +3.1% | +4.0% | +1.5% | -2.3% | -1.1% | +3.2% |
| SOLV | Healthcare | UBSB | Upgrade | Neutral → Buy | $95 | $13.9B | $80.47 | +3.2% | +7.1% | +2.8% | -2.0% | -1.6% | +3.1% |
| COO | Healthcare | UBS | Initiates | Neutral | $75 | $13.7B | $70.29 | +1.6% | +2.5% | +1.4% | -0.6% | -0.5% | +2.6% |
| FMS | Healthcare | BNP Paribas Exane | Downgrade | Neutral → Underperform | $20 | $13.4B | $24.87 | -1.5% | -0.5% | +0.4% | +3.4% | -0.2% | -1.6% |